Novartis Collaborates with DNDi to Develop LXE408 for Visceral Leishmaniasis

 Novartis Collaborates with DNDi to Develop LXE408 for Visceral Leishmaniasis

Novartis Collaborates with DNDi to Develop LXE408 for Visceral Leishmaniasis

Shots:

  • Novartis will conduct P-I clinical study and will be responsible for the development and regulatory submissions while DNDi will lead P- II & III clinical development with the expected initiation of P-II study in H1’21 in India and additional trials planned in East Africa
  • The collaboration b/w the companies is supported with the broader program with the Wellcome Trust and other partners to develop new therapies for visceral leishmaniasis and cutaneous leishmaniasis
  • The broader program brings together a strong consortium of R&D partners, including the University of Dundee, GSK, Pfizer, TB Alliance & Takeda. LXE408 is a first-in-class oral therapy, discovered at Novartis with financial support from the Wellcome Trust

Click here to­ read full press release/ article | Ref: Novartis | Image: PMLive

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post